Nadir CA-125 Level Is an Independent Prognostic Factor in Advanced Epithelial Ovarian Cancer

被引:23
|
作者
Kang, Sokbom [1 ]
Seo, Sang-Soo [1 ]
Park, Sang-Yoon [1 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Branch Uterine Canc, Goyang 411769, South Korea
关键词
ovarian cancer; CA-125; cytoreductive surgery; prognostic factor; progression free survival; GYNECOLOGIC-ONCOLOGY-GROUP; CA125; CONCENTRATION; THERAPY; CHEMOTHERAPY; PACLITAXEL; CARCINOMA; SURVIVAL; PLATINUM; SURGERY; TRIAL;
D O I
10.1002/jso.21258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of this study was to determine the independency of a nadir CA-125 level as a prognostic factor in patients with advanced epithelial ovarian cancer (EOC). Methods: Among the 153 women with advanced EOC who had surgery in our hospital between January 2001 and June 2007, 121 women underwent retrospective chart review. Results: Sixty-six patients (57.9%) had nadir CA-125 values <= 10 U/ml. The CA-125 levels at the time of diagnosis was associated with the nadir CA-125 (P = 0.018). The median progression-free survival (PFS) in patients with nadir CA-125 levels <= 10 and 10-35 U/ml was 32.4 and 16.8 months, respectively (P = 0.0001). A multivariate Cox hazard model revealed that the nadir CA-125 value and the residual tumor size >= 0.5 cm were independently associated with the PFS (P = 0.001 and 0.014). Within the subgroup who underwent primary debulking surgery, the significant association between the PFS and the nadir CA-125 value was preserved (P = 0.001). Conclusions: The prognostic role of the nadir CA-125 is independent of residual tumor size in the patients with advanced EOC. However, it is still unclear whether maximal surgical effort can affect the nadir CA-125 levels. J. Surg. Oncol. 2009;100:244-247. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [31] Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer
    Uzunoglu, Sernaz
    Aybatli, Aysun
    Kaplan, Petek Balkanli
    Cicin, Irfan
    Sut, Necdet
    Sayin, Cenk
    Varol, Fusun
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [32] Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
    Diaz-Padilla, Ivan
    Razak, Albiruni Ryan Abdul
    Minig, Lucas
    Bernardini, Marcus Q.
    del Campo, Josep Maria
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (01): : 15 - 20
  • [33] Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer
    Lin, Yu-Han
    Wu, Chen-Hsuan
    Fu, Hung-Chun
    Chen, Yu-Jen
    Chen, Yin-Yi
    Ou, Yu-Che
    Lin, Hao
    CANCER BIOMARKERS, 2020, 28 (03) : 285 - 292
  • [34] Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
    Iván Díaz-Padilla
    Albiruni Ryan Abdul Razak
    Lucas Minig
    Marcus Q. Bernardini
    Josep María del Campo
    Clinical and Translational Oncology, 2012, 14 : 15 - 20
  • [35] Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
    Markmann, M
    Liu, PY
    Rothenberg, ML
    Monk, BJ
    Brady, M
    Alberts, DS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1454 - 1458
  • [36] SENSITIVITY OF NADIR CA-125 AND HE-4 LEVELS AS PROGRESSION-FREE INDICATORS OF EPITHELIAL OVARIAN CANCER
    Potemin, S.
    Kazantseva, M.
    Porhanova, N.
    Syrota, L.
    Syrota, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [37] CA-125, A MARKER OF OVARIAN EPITHELIAL TUMORS
    RUIBAL, A
    MEDICINA CLINICA, 1988, 91 (02): : 54 - 57
  • [38] Limitations to the use of the CA-125 antigen level in ovarian cancer
    Maurie Markman
    Current Oncology Reports, 2003, 5 (4) : 263 - 264
  • [39] CA-125 level preoperative assessment in early and advanced ovarian carcinoma
    Raspollini, Maria Rosaria
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 356 - 357
  • [40] Comparative Study Between Serum Level of Lysophosphatidic Acid and CA-125 in Epithelial Ovarian Cancer
    Rady H.A.
    Othman M.M.
    Agamia A.F.M.
    Mahmoud M.H.
    Elghrabawy S.A.
    Indian Journal of Gynecologic Oncology, 2018, 16 (3)